Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | FGFR2 amp |
Therapy | Infigratinib |
Indication/Tumor Type | stomach cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR2 amp | stomach cancer | sensitive | Infigratinib | Phase II | Actionable | In a Phase II trial (LB1001-201), Truseltiq (infigratinib) treatment in patients with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma with FGFR2 amplification resulted in a response rate of 25%, disease control rate of 80%, median duration of response of 3.8 months, median progression-free survival of 3.3 months, median overall survival of 8 months, with 15 of 19 patients experiencing tumor shrinkage (Ann Oncol 34 (2023): S761-S762; NCT05019794). | detail... |
FGFR2 amp | stomach cancer | sensitive | Infigratinib | Preclinical | Actionable | In a preclinical study, Truseltiq (infigratinib) inhibited proliferation of gastric cancer cell lines harboring FGFR2 amplification in culture (PMID: 26036639). | 26036639 |
FGFR2 amp | stomach cancer | sensitive | Infigratinib | Preclinical - Cell culture | Actionable | In a preclinical study, Truseltiq (infigratinib) inhibited growth of a gastric cancer cell line harboring FGFR2 amplification in culture (PMID: 30045926). | 30045926 |
PubMed Id | Reference Title | Details |
---|---|---|
(26036639) | FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro. | Full reference... |
(30045926) | Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer. | Full reference... |
1527P Efficacy and safety of infigratinib in locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma patients with FGFR2 gene amplification | Full reference... |